Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Evotec SE appointed Dr. Joanna Holbrook as Chief Scientific Officer and member of the Management Board, effective November 1, 2026. Holbrook brings 25+ years of R&D leadership, most recently as Therapy Area Head for cardiovascular, renal and hepatic disease at Novo Nordisk, with prior roles at Biomodal, BenevolentAI and GSK.
Key figures
- Effective date
- November 1, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.